GOVERNMENT OF INDIA

Directorate General of Health Services
Central Drugs Standard Control Organization
(Global Clinical Trial Division)
FDA Bhawan, Kotla Road, New Delhi-110002
Te No: 01123236965, Fax: 01123236971
E-mail: dci@nic.in

File No: CT/17/000059

To,
M/s. Excel Life sciences Pvt. Ltd.,
D-62, 1st Floor, Sector-2,
Noida-201301, India.

Subject: Clinical Trial Titled **"A Phase 3 Randomized, Controlled, Open-Label Study of Selinexor, Bortezomib and Dexamethasone (SVD) Versus Bortezomib and Dexamethasone (VD) In Patients with Relapsed or Refractory Multiple Myeloma (RRMM) "–** regarding.

Reference: Your online application reference No. GCT/Form44/FF/2017/4396 (GCT/61/17) dated 02/Aug/ 2017.

Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs & Cosmetics Rules under supervision of the investigators mentioned in below and as per the **Protocol No: KCP-330-023 Version No. 3.0** (**Amendment 2**) **dated 06/April/2017** submitted to this Directorate.

1. Dr. Anita Ramesh, Department of Medical Oncology, Saveetha Medical College and Hospital Saveetha Nagar, Thandalam, Chennai-602105, Tamil Nadu, India.
2. Dr. Akshay D Shah, S.L. Raheja (A Fortis Associate) Hospital Raheja Rugnalaya Marg, Mahim West, Mumbai-400016, Maharashtra, India.
3. Dr. Dinesh Bhurani, Rajiv Gandhi Cancer Institute and Research Centre, Sector-5, Rohini, delhi-110085, India.
4. Dr. Ganesh Shivlingrao Jaishetwar, Yashoda Hospital, Block-B, Rajbhavan Road, Somajiguda, Hyderabad-500082, Telangana, India.
5. Dr. Bhavin Shah, Sterling Hospital, Sterling Hospital Road, Memnagar, Ahmedabad-380052, Gujarat, India.
6. Dr. Dinesh Kumar Sinha, Department of Oncology, Regional Cancer Centre, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna-800014, Bihar, India.
7. Dr. Sourav Kumar Mishra, Institute of Medical Sciences and SUM Hospital, K-8 Kalinga Nagar, Ghatikia, Bhubaneswar-751003, Odisha, India.
8. Dr. Niti Raizada, Dept. of Medical Oncology, Fortis Hospital, 154/9, Bannerghatta Road, Opp. IIM-B, Bangalore-560076, Karnataka, India.
9. Dr. Suresh. H. Advani, Dept. of Medical Oncology, Jaslok Hospital and Research Centre 15-Dr. G. Deshmukh Marg, Mumbai-400026, Maharashtra, India.
10. Dr. Prasanth Ganesan, Dept. of Medical Oncology, Cancer Institute (WIA), Sardar Patel Road, Adyar, Chennai-600020, TamilNadu, India.
11. Dr. Sivanesan Balasubramanian, G. Kuppuswamy Naidu Memorial Hospital, P.B. No. 6327, Nethaji Road, Pappanaickenpalayam, Coimbatore-641037, Tamil Nadu, India.

12. Dr. Ranjan Kumar Mohapatra, SRM Institutes for Medical Science, No. 1, Jawaharlal Nehru Salai 100 Feet Road, Vadapalani, Chennai-600026, Tamil Nadu, India.
13. Dr. NirmalVivekRaut, Bhakti Vedanta Hospital and Research Institute, Srishti Complex, Bhaktivedanta Swami Marg, Mira Road (East) Thane-401107, Maharashtra, India.
14. Dr. Atul Batra, Department of Medical Oncology Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, India.
15. Dr. Jeevan Kumar, Tata Medical Centre, Department of Clinical Hematology 14 MAR (E-W), New Town, Rajarhat, Kolkata-700160, West Bengal, India.
16. Dr. Shailendra Prasad Verma, King George's Medical University, Shah Mina Road, Chowk Lucknow, Uttar Pradesh-226003, India.
17. Dr. Minish Mahendra Jain, Grant Medical Foundation, Ruby Hall Clinic 40, Sassoon Road, Pune-411001, Maharashtra, India.
18. Dr. Ashutosh Panigrahi, Department of Medical Oncology, All India Institute of Medical Sciences, Sijua, Patrapada, PO-Dumduma, Bhubaeswar, Odisha-751019, India.
19. Dr. Sreejith G. Nair, Department of Medical Oncology, Regional Cancer Centre, Medical College Campus, Post Box No. 2417, Thiruvananthapuram-695011, Kerala, India.
20. Dr. Pankaj Malhotra, Dept. of Internal Medicine, Nehru Hospital, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh-160012, India.
21. Dr. Amit Kumar Dhiman, Dept. of Oncology, Dayanand Medical College and Hospital, Tagore Nagar, Civil Lines, Ludhiana-141001, Punjab, India.
22. Dr. Krishna Kumar Rathnam, Dept. of Oncology, Meenakshi Misson Hospital and Research Centre, Lake |Area, Melur Road, Madurai-625107, Tamil Nadu, India.
23. Dr. Tuphan Kanti Dolai, Dept. of Haematology, Nil Ratan Sircar Medical College and Hospital 138, Acharya Jagadish Chandra Bose Road, Sealdah, Kolkata, West Bengal-700014, India.
24. Dr. Asis Mukhopadhyay, Netaji Subhas Chandra Bose Cancer Research Institute 16-A, Park Lane, Kolkata-700016, West Bengal, India.

Note that the clinical trial permission is subject to the following conditions:

a. Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y, Good Clinical Practice Guidelines issued by this Directorate and other applicable regulations.

b. Approval of the Ethics Committee shall be obtained before initiation of the study.

c. Clinical trials shall be registered at Clinical trials Registry of India before enrolling the first patient for the study.

d. Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority, and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority.

e. Any report of serious adverse event occurring during clinical trial study to the subject, after due analysis, shall be forwarded within 14 days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y.

f. In case of an injury or death during the study to the subjects, the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with rule 122 DAB

and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority.

g. The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trial in India and other applicable regulations.

h. The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites and the Investigator shall allow officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs, etc. related to clinical trial and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial.

i. Clinical trial shall be conducted only at those sites which are institutes/hospitals having adequate emergency facilities and duly registered Institutional Ethics committees.

j. The details of payment/honorarium/financial support/fees paid by the Sponsor to the Investigator(s) for conducting the study shall be made available to this directorate before initiation of each of the trial sites.

k. An audio-video recording of the informed consent process in case of vulnerable subjects in clinical trials of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record. Provided that in case of clinical trial of anti-HIV and anti-Leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record.

l. It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

m. Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect as per the requirements specified in Appendix V of Schedule Y of the Drugs and Cosmetics Rules, 1945 must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

Yours faithfully,

GYANENDRA NATH SINGH
Digitally signed by GYANENDRA NATH SINGH
Date: 2017.11.08 17:17:15 +05'30'

(Dr. G.N. Singh)
Drugs Controller General (I)